MASSACHUSETTS STANDARD FORM FOR SYNAGIS® PRIOR AUTHORIZATION REQUESTS

*Some plans might not accept this form for Medicare or Medicaid requests.

A. Destination				
Health Plan or Prescription Plan Name:				
Health Plan Phone:		Health Plan Fax:		
B. Patient Information				
Patient Name:	DOB:		Gender: Male Female Other:	
Member ID #:				
C. Prescriber Information				
Prescribing Clinician:		Phone #:		
oecialty:		Secure Fax #:		
NPI #:		DEA #:		
Prescriber Point of Contact (POC) Name (if different than prescriber):				
POC Phone #:		POC Secure Fax #:		
POC Email (not required):				
Prescribing Clinician or Authorized Representative Signature:				
Date:				
D. Medication Information — SYNAGIS® (palivizumab)		Action to see a		
Check if Expedited Review/Urgent Request: [(In checking this box, I attest to the fact that this request meets the definition and criteria for expedited review and is an urgent request.)				
Is the patient currently being treated with the drug requested? Yes No				
f yes, date started: Date of last dose received: Number of doses received:				
Number of doses requested:				
E. Patient Clinical Information				
Primary Diagnosis Related to Medication Request:				
ICD Code(s):				
Gestational age: # weeks: # days:		=	" .	
Birth weight: Current weight: Date current weight recorded:				
Pertinent Concurrent Medications:				
Allergies:				
A III				

K CALLED TO THE CONTROL OF THE CONTR	nittee on Infectious Disease and Bronchiolitis Guidelines)
Chronic Lung Disease (CLD)	CLD of prematurity defined as gestational age ≤31 weeks, 6 days, AND requirement for 21% oxygen for at least the first 28 days after birth <12 months of age with CLD
	☐ 12–24 months of age with CLD AND continues to require medical support during the 6-month period before second RSV season AND
	Supplemental oxygen (dates):
	☐ Diuretic therapy (drugs/dates):
	☐ Chronic corticosteroids (drugs/dates):
	Other
	Chronic Respiratory Disease arising in the perinatal period: Wilson-Mikity Syndrome (P27.0)
	Bronchopulmonary Dysplasia originating in the perinatal period (P27.1)
	Other chronic respiratory disease originating in the perinatal period (P27.8)
·	Congenital Abnormality of the Lungs:
Congenital Heart Disease (CHD)	<12 months of age at start of season with hemodynamically significant CHD such as:
	 Acyanotic heart disease and receiving medication to control congestive heart failure and surgery to correct
	(drugs/dates):
	(surgery date):
	☐ Moderate to severe pulmonary hypertension
	Other (describe):
	☐ 12–24 months of age undergoing cardiac transplant during RSV season (date of planned surgery):
	☐ Cyanotic Heart Disease — Diagnosis:
Airway/Neuromuscular Conditions	<12 months of age at start of season and compromised handling of secretions AND due to:
	☐ Significant abnormality of the airway (attach clinical notes)
	☐ Neuromuscular condition (attach clinical notes)
Prematurity	☐ ≤GA 28 weeks, 6 days AND <12 months at start of season
Other medical conditions or history	☐ Cystic Fibrosis ☐ Down's Syndrome ☐ Immunocompromised
	☐ Describe other relevant medical history:
Complete this section for Profession	nally Administered Medications (including Buy and Bill)
Start Date:	End Date:
Servicing Prescriber/Facility Name:	☐ Same as Prescribing Clinician
Servicing Provider/Facility Address:	
Servicing Provider NPI/Tax ID #:	
Name of Billing Provider:	
Billing Provider NPI #:	
Is this a request for reauthorization? Yes No	
	J Code: # of Units:

Providers should consult the health plan's coverage policies, member benefits, and medical necessity guidelines to complete this form.

Providers may attach any additional data relevant to medical necessity criteria.